acnnewswire.com
Positiveen.acnnewswire.com ·
dr. shui on leung invited to the 2026 lifearc translational science summit in the uk
WB_2453_ORGANIZED_CRIMEWB_2433_CONFLICT_AND_VIOLENCEWB_2432_FRAGILITY_CONFLICT_AND_VIOLENCEWB_2456_DRUGS_AND_NARCOTICS
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedThe article covers a scientific presentation by SinoMab's CEO, highlighting early-stage clinical progress for SM17. No commercial mechanism (pricing, supply, revenue, margin) is triggered; the event is a research update with no concrete financial or operational impact. The commercial pathway is weak and too early stage.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Dr. Shui On Leung presented at the 2026 LifeArc Translational Science Summit in London on May 13, 2026.
- SinoMab's SM17 (anti-IL-25 receptor) showed promising Phase 1b results for atopic dermatitis.
- Phase II trial for SM17 began in mainland China on March 31, 2026, targeting ~210 participants.